



# Agenda | Management Board

## 65<sup>th</sup> Meeting

---

Date      **21 June 2022**      Chair      **Franz Pietsch**

---

Venue      **Lisbon and video conference (Webex)**

---

**Tuesday, 21 June 2022**  
**9.00 – 17.00 (Lisbon time)**

9.00 – 11.00

### **1. Introduction by the Chair**

### **2. Adoption of the agenda**

2.1. Annotated agenda

EMCDDA/01/22 rev1  
EMCDDA/02/22

### **PART I: Exchange of views**

### **3. Exchange of views on the drugs situation in Ukraine (for discussion)**

3.1. Presentation by the EMCDDA and general discussion

EMCDDA/03/22

### **PART II: Items for decision and information**

### **4. State of play of the negotiations on the EC proposal for a new Regulation on the EU Drugs Agency (for information):**

- Presentation about the outcome and state of play of the revised text as adopted by the Council by the member of France
- Oral report by the European Commission
- Information on financial, administrative and legal issues for non-EU EMCDDA members by the representative of Turkey and member of Norway
- Remarks from the EMCDDA Director

### **5. International cooperation:**

5.1. Oral introduction by the Director on strategic highlights of EMCDDA international cooperation (for information)

- Candidate countries and potential candidate partners:

5.2. The EMCDDA/IPA7 project (Instrument for Pre-Accession Assistance) (for information)

EMCDDA/04/22

- European Neighbourhood Partner Countries:

5.3. 'EU4 Monitoring Drugs' project (for information)

EMCDDA/05/22

5.4. EMCDDA Technical cooperation project with Georgia (for information)

EMCDDA/06/22

- Other non-EU countries:

5.5. Suspension of the cooperation between the EMCDDA and the Russian Federation (for information)

5.6. Mandate for negotiating a Working Arrangement between the EMCDDA and DEVIDA (Peru) (for decision)

EMCDDA/07/22

5.7. COP III project (COPOLAD - Cooperation Programme between Latin America, the Caribbean and the EU on Drugs Policies) (for information)

EMCDDA/08/22

- Other EU Agencies:

5.8. Working Arrangement with the European Union Agency for Law Enforcement Training (CEPOL) (*for adoption*)

EMCDDA/09/22

11.00 – 11.15 Break

11.15 – 12.30

### **PART III: Items for decision and information**

#### **6. Joint EMCDDA-Europol EU Drug Markets Report 2022 (*for information*)**

6.1. Presentation by the EMCDDA of the modules on cocaine and methamphetamine

EMCDDA/10/22

#### **7. Activity reports:**

7.1. Report on the activities of the Chair (*for information*)

EMCDDA/11/22

7.2. Report from the Budget Committee (*for information*)

EMCDDA/12/22

7.3. Report on the external activities of the Director (*for information*)

EMCDDA/13/22

12.30 – 14.00 Lunch

14.00 – 17.00

### **PART IV: Items for decision and information**

#### **8. Presentations by the EU Presidencies:**

8.1. Presentation on the conclusions of the French Presidency (*for information*)

EMCDDA/14/22

8.2. Presentation on the programme of the Czech Presidency (*for information*)

EMCDDA/15/22

#### **9. Eurobarometer survey on the impact of drugs on communities in the EU (*for information*)**

EMCDDA/16/22

#### **10. Budget and financial issues:**

10.1. EMCDDA 2021 final accounts: opinion of the Management Board (*for adoption*)

EMCDDA/17/22

10.2. Information on procurements for non-administrative activities of a value greater than EUR 60 000 to implement the 2022 work programme (*for information*)

EMCDDA/18/22

10.3. EMCDDA's budget for 2023: Oral report on the state of play by the European Commission (*for information*)

#### **11. EMCDDA Scientific Committee:**

11.1. Renewal of the mandate of the EMCDDA Scientific Committee (*for decision*)

EMCDDA/19/22

11.2. Renewal of the list of experts to extend the Scientific Committee for the purposes of the risk assessment of new psychoactive substances (*for decision*)

EMCDDA/20/22

#### **12. Performance:**

12.1. State of implementation of the recommendations issued by the Internal Audit Service (IAS) (*for information*)

EMCDDA/21/22

#### **13. Prevention and management of conflicts of interest:**

13.1. Periodic assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers (*for decision*)

EMCDDA/22/22

#### **14. Any other business**

14.1. Fourth European Conference on addictive behaviours and dependencies, Lisbon, 23–25 November 2022: presentation by the Portuguese delegation (*for information*)

EMCDDA/23/22

14.2. Planning of meetings for 2023 (*for endorsement*)

EMCDDA/24/22

17.00 **Gathering with the EMCDDA staff (Cais do Sodré)**